Quality of Life and Adherence to Imatinib Mesylate Therapy in Chronic Myeloid Leukemia Patients at Dharmais Cancer Hospital Jakarta

Nisha Virginia, Maksum Radji, Lucia Rizka Andalucia


Background: Quality of life and adherence to long-term imatinib mesylate (IM) therapy is a major factor in achieving therapeutic effects in patients with chronic myeloid leukemia (CML). However, the data of the quality of life and adherence level is inconsistent in various studies and is also not fully understood yet in Indonesia.

Methods: This is an observational study (single-centered) using a cross-sectional design. CML patients older than 18 years old with National Health Insurance (JKN) at the Dharmais Cancer Hospital (RSKD) Jakarta who used IM for at least one month were tested using the Medication Adherence Questionnaire (MAQ) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) from March to April 2020.

Result: A total of 50 CML patients were included in the study (male: female ratio = 1.08: 1), had a good median score of global health status/QoL, and had a good function and symptom scales, except for the fatigue symptom scale (median: 33.33; 25th percentile - 75th percentile: 11.11– 44.44). The patient adherence rate was dominated by adherent patients (20/50; 40.0%). Comparative analysis revealed that the scale of QoL (p = 0.028) and fatigue (p = 0.094) variables showed statistically significant differences between adherent and non-adherent subjects.

Conclusions: This study showed that two-fifth of patients were considered to be non-adherent. Adherent patients were known to have higher QoL than non-adherent patients. Meanwhile, patients with severe symptoms of fatigue were found to be non-adherent to IM therapy.


adherence, chronic myeloid leukemia, imatinib mesylate, quality of life


Deininger MW, Shah NP, Altman JK, et al. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020;18(10):1385–1415.

Kantarjian H, Cortes J. Chronic myeloid leukemia. In: Longo DL, editor. Harrison’s Hematology and Oncology. 3rd ed. United States: McGraw-HIll Education; 2017. p. 181.

Baccarani M, Castagnetti F, Gugliotta G, Rosti G. A review of the European LeukemiaNet recommendations for the management of CML. Ann Hematol. 2015;94:141–7.

Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv41–51.

World Health Organization. Adherence to Long-Term Therapies: Evidence for Action [Internet]. Switzerland: World Health Organization; 2003. 7 p. Available from:


Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. Cancer Spectrum Knowl Environ. 2002;94(9):652–61.

Alves AR, Lima WG, Nagai MM, et al. Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia. Brazilian J Pharm Sci. 2016;52(4):581–90.

Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381–8.

Noens L, van Lierde MA, De Bock R, et al. Prevalence , determinants , and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood J. 2009;113(22):5401–11.

Wu EQ, Johnson S, Beaulieu N, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin. 2010;26(1):61–9.

Hahn EA, Glendenning GA. Quality of life on imatinib. Semin Hematol. 2003;40(2 SUPPL. 2):31–6.

Flynn KE, Atallah E. Quality of life and long term therapy in patients with chronic myeloid leukemia. Physiol Behav. 2017;176(12):139–48.

Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int. 2015;2015:1–12.

Hening WN, Sartika RAD, Sauriasari R. Effect of hospital pharmacist counseling on clinical outcomes of type 2 diabetes mellitus outpatients. J Res Pharm Pract. 2019;6(October):158–65.

Nguyen TMU, La Caze A, Cottrell N. Validated adherence scales used in a measurement-guided medication management approach to target and tailor a medication adherence intervention: A randomised controlled trial. BMJ Open. 2016;6(11):1–10.

Perwitasari DA, Atthobari J, Dwiprahasto I, et al. Translation and validation of EORTC QLQ-C30 into Indonesian version for cancer patients in Indonesia. Jpn J Clin Oncol. 2011;41(4):519–29.

Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.

Fayers PM, Aaronson NK, Bjordal K, et al. The EORTC QLQ-C30 Scoring Manual [Internet]. 3rd ed. EORTC QLQ-C30 Scoring Manual. Brussels: European Organisation for Research and Treatment of Cancer; 2001. Available from: https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf

Jabbour E, Saglio G, Radich J, Kantarjian H. Adherence to BCR-ABL inhibitors: issues for CML therapy. Clin Lymphoma Myeloma Leuk. 2012;12(4):137–43.

Unnikrishnan R, Veeraiah S, Mani S, et al. Comprehensive evaluation of adherence to therapy, its associations, and its implications in patients with chronic myeloid leukemia receiving imatinib. Clin Lymphoma Myeloma Leuk. 2016;16(6):366-371.e3.

Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648–71.

Efficace F, Stagno F, Iurlo A, et al. Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. Leukemia. 2020;34(2):488–98.

Uğur MC, Kutbay YB, Kaya ÖÖ, Ceylan C. Assessment of Quality of Life of Chronic Myeloid Leukemia Patients by Using the EORTC QLQ-C30. Turkish J Hematol. 2017;34(2):184–99.

Williams LA, Gonzalez AGG, Ault P, et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood. 2013;122(5):641–7.

Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011;118(17):4554–60.

Efficace F, Baccarani M, Breccia M, et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia. 2013;27(7):1511–9.

Wang Y, Zhang P, Han Y, et al. Adherence to adjuvant imatinib therapy in patients with gastrointestinal stromal tumor in clinical practice: a cross-sectional study. Chemotherapy. 2019;430022(1277).

Cella D, Nowinski CJ, Frankfurt O. The impact of symptom burden on patient quality of life in chronic myeloid leukemia. Oncol. 2014;87(3):133–47.

Moulin SMM, Eutrópio FJ, Souza JO, et al. The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms. Support Care Cancer. 2017;25(3):951–5.

Efficace F, Cannella L. The value of quality of life assessment in chronic myeloid Leukemia patients receiving tyrosine Kinase Inhibitors. Hematology. 2016;2016(1):170–9.

Full Text: PDF

DOI: 10.33371/ijoc.v15i3.800

Article Metrics

Abstract view : 69 times
PDF - 33 times


  • There are currently no refbacks.

Copyright (c) 2021 Indonesian Journal of Cancer

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.